Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Framework for equitable allocation of COVID-19 vaccine
  • Published Date:
    October 2020
  • Source:
    Consensus study report highlights
  • Language:
Filetype[PDF-284.78 KB]

  • Description:
    In response to the coronavirus disease 2019 (COVID-19) pandemic and the societal disruption it has brought to people around the world, national gov- ernments and the international community have invested billions of dollars into the development of safe and effective vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. Mass vaccination against SARS-CoV-2, along with other public health strategies, offers the best opportunity to protect the public from COVID-19 by significantly reducing transmission, illness, and deaths. Still, even if one or more COVID-19 vaccines under development are approved for use, it is unlikely that enough doses will be immediately available to vaccinate large portions of the population. Government officials who will oversee COVID-19 vaccination plans urgently need guidance on how to allocate and distribute limited vaccine supplies equitably until the global supply is sufficient to develop widespread protection against COVID-19. To address this need, the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health asked the National Academies of Sciences, Engineering, and Medicine, in partnership with the National Acad- emy of Medicine, to convene an ad hoc committee that would develop an overarching framework for vaccine allocation that could assist policy makers in the domestic and global health communities. The resulting report, Framework for Equitable Allocation of COVID-19 Vaccine, presents such a framework and discusses important implementation considerations related to coordination, cost, risk communication, community engagement, vaccine acceptance, and global allocation. Study sponsors: Centers for Disease Control and Prevention, National Institutes of Health. To read the full report, please visit nationalacademies.org/covidvaccineframework
  • Main Document Checksum:
No Related Documents.
You May Also Like: